A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein.
about
Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides.Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusionStructural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.The M-T Hook Structure Is Critical for Design of HIV-1 Fusion InhibitorsHIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodiesImproved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide StrategyAntibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutIdentification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion.Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp413-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoproteinHIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodiesAn antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion.Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission.Fab crystallization and preliminary X-ray analysis of NC-1, an anti-HIV-1 antibody that recognizes the six-helix bundle core of gp41.Residues in the membrane-spanning domain core modulate conformation and fusogenicity of the HIV-1 envelope glycoprotein.Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediatesGenetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sitesDesigning a soluble near full-length HIV-1 gp41 trimer.In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.Variable sensitivity to substitutions in the N-terminal heptad repeat of Mason-Pfizer monkey virus transmembrane protein.Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor designMechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket
P2860
Q24791794-1FDE4EB3-5E3E-485F-ACBA-0D3FA8C44B65Q24794033-0C04B21A-D605-41B0-9953-30C7A5DE5018Q27619600-0C00C54C-7F3A-460D-A112-5271459CD4B7Q27635422-90FD5CD4-6775-480F-9ECC-F4AD23B260B5Q27671434-BEC86A6B-DADF-4E9A-BBC7-F0ED71161B02Q28485218-945ACD3B-57A7-48F6-B4B1-0D6A7DDB091DQ30436401-C3E6296F-0F1A-4CCD-B77E-4BB8EA8FDDFCQ30661709-D024FE46-9C6D-477F-960B-F8025400292CQ30843874-D5963856-292E-4978-8655-745E4D11DDD8Q33208281-E962A14A-8241-4559-8194-6FFF056737ECQ33269255-43266DFA-E8E3-4644-87BE-68D361D5F842Q33272711-016F7753-4780-4289-BED2-612C9F06DBF7Q33356323-73B7AC41-0F8B-4964-BC07-B5419CBABA78Q33495440-91544C48-2818-442A-A985-CCB848E8DE41Q33622229-E192F546-4893-4778-B39E-36AF608D2807Q33648376-EE140649-13AA-4C3F-AD44-97CAE7142FE8Q33806056-0AEDCC2C-9525-473E-9B36-2ECA3F8BFB01Q33807129-D7C90409-9497-4B45-A475-DC3280A39F54Q33826278-D074EF9F-D086-4EC1-866E-07739CA9EBE2Q33854904-BC155FE6-7356-4D4C-B4A1-EFB1CB1E4FDBQ33869882-32027E60-5AAD-44BE-AD9A-964D75CC0A02Q33877501-BBC83B47-BFB4-4204-8576-0083F75466F7Q33925615-091829B0-FBB2-4730-9EA4-3A349813FA24Q33967511-86B88E90-8BFD-421E-8200-98A426172E05Q33987533-773BB7F1-F088-4501-AEAF-72879316E5BEQ34225654-C2831EFD-6113-4DA0-A261-7909BC3C4E3EQ34341098-CC0BF20C-C6AB-462A-A52B-FD027433F724Q34342264-E2BA2B2C-0094-48E2-B44B-EAA90BA066A7Q34359035-4AC936A8-09C7-4BDF-BEE0-151EC82CB895Q34361680-F2B6DB37-EE00-491B-9EB4-25EE7410BF24Q34466260-EB902017-6CFB-4924-9ADC-C30768F52A92Q34489464-66AF2AB7-9AA8-45E0-BD2F-395F005DE05BQ34536817-052712D3-73D9-49B7-A4ED-579BCB99AF42Q34545861-99D10EE2-CCEE-4E72-B5C0-066BB1EE8C81Q34761552-8BB03D74-D311-4D31-A525-7EE183F4FE17Q34778515-5157702D-8C48-4E2F-A9F9-B2443BD5BAD8Q34981730-7C997316-2DF3-4874-9A83-015D64C3AF62Q35105124-8957CE3D-7739-4239-939A-C03AFBBDCC16Q35563298-C52869AB-31BC-4D35-9A1C-4226B17997C3Q35641194-68B3D133-2F4F-4562-BB82-19563232549C
P2860
A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
A conformation-specific monocl ...... type 1 envelope glycoprotein.
@en
A conformation-specific monocl ...... type 1 envelope glycoprotein.
@nl
type
label
A conformation-specific monocl ...... type 1 envelope glycoprotein.
@en
A conformation-specific monocl ...... type 1 envelope glycoprotein.
@nl
prefLabel
A conformation-specific monocl ...... type 1 envelope glycoprotein.
@en
A conformation-specific monocl ...... type 1 envelope glycoprotein.
@nl
P2093
P2860
P1433
P1476
A conformation-specific monocl ...... s type 1 envelope glycoprotein
@en
P2093
P2860
P304
10213-10217
P407
P577
1998-12-01T00:00:00Z